Susanna Gatti High Sells 10,163 Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) COO Susanna Gatti High sold 10,163 shares of Dyne Therapeutics stock in a transaction on Monday, June 24th. The stock was sold at an average price of $35.33, for a total transaction of $359,058.79. Following the completion of the transaction, the chief operating officer now owns 148,792 shares in the company, valued at approximately $5,256,821.36. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Susanna Gatti High also recently made the following trade(s):

• On Friday, June 21st, Susanna Gatti High sold 29,787 shares of Dyne Therapeutics stock. The stock was sold at an average price of $35.01, for a total transaction of $1,042,842.87.
• On Wednesday, June 12th, Susanna Gatti High sold 40,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $33.36, for a total transaction of $1,334,400.00.
• On Monday, June 10th, Susanna Gatti High sold 80,000 shares of Dyne Therapeutics stock. The stock was sold at an average price of $30.24, for a total transaction of $2,419,200.00.
• On Thursday, May 16th, Susanna Gatti High sold 2,738 shares of Dyne Therapeutics stock. The stock was sold at an average price of $28.27, for a total transaction of $77,403.26.

Dyne Therapeutics Trading Up 1.7 %

Shares of DYN stock opened at $35.63 on Tuesday. Dyne Therapeutics, Inc. has a 1 year low of $6.40 and a 1 year high of $36.60. The firm’s 50 day moving average is $29.19 and its 200-day moving average is $24.03. The firm has a market capitalization of $3.11 billion, a price-to-earnings ratio of -8.97 and a beta of 1.06.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Thursday, May 2nd. The company reported ($0.81) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.81). On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several large investors have recently bought and sold shares of the business. Principal Financial Group Inc. lifted its holdings in Dyne Therapeutics by 5.9% in the first quarter. Principal Financial Group Inc. now owns 15,403 shares of the company’s stock valued at $437,000 after buying an additional 857 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in Dyne Therapeutics in the first quarter valued at approximately $28,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Dyne Therapeutics by 5.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 22,921 shares of the company’s stock valued at $305,000 after buying an additional 1,199 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Dyne Therapeutics by 28.0% in the first quarter. Ameritas Investment Partners Inc. now owns 5,896 shares of the company’s stock valued at $167,000 after buying an additional 1,291 shares during the period. Finally, Russell Investments Group Ltd. lifted its holdings in Dyne Therapeutics by 1.4% in the first quarter. Russell Investments Group Ltd. now owns 101,943 shares of the company’s stock valued at $2,894,000 after buying an additional 1,447 shares during the period. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on DYN shares. Stifel Nicolaus upped their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Oppenheimer reissued an “outperform” rating and issued a $47.00 target price on shares of Dyne Therapeutics in a research note on Monday, May 6th. HC Wainwright upped their target price on shares of Dyne Therapeutics from $36.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, May 20th. Morgan Stanley started coverage on shares of Dyne Therapeutics in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $40.00 target price on the stock. Finally, Piper Sandler boosted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $40.78.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.